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Abstract
Background: Comprehensive analyses have recently been performed on many human cancer tissues, leading to the
identification of a number of mutated genes but providing no information on the variety of mutations present in each of
them. This information is of interest to understand the possible origin of gene mutations that cause tumors.
Methodology/Principal Findings: We have analyzed the sequence heterogeneity of the transcripts of the human HPRT and
G6PD single copy genes that are not considered tumor markers. Analyses have been performed on different colon cancers
and on the nearby histologically normal tissues of two male patients. Several copies of each cDNA, which were produced by
cloning the RT-PCR-amplified fragments of the specific mRNA, have been sequenced. Similar analyses have been performed
on blood samples of two ostensibly healthy males as reference controls. The sequence heterogeneity of the HPRT and G6PD
genes was also determined on DNA from tumor tissues. The employed analytical approach revealed the presence of low-
frequency mutations not detectable by other procedures. The results show that genetic heterogeneity is detectable in HPRT
and G6PD transcripts in both tumors and nearby healthy tissues of the two studied colon tumors. Similar frequencies of
mutations are observed in patient genomic DNA, indicating that mutations have a somatic origin. HPRT transcripts show
genetic heterogeneity also in healthy individuals, in agreement with previous results on human T-cells, while G6PD
transcript heterogeneity is a characteristic of the patient tissues. Interestingly, data on TP53 show little, if any, heterogeneity
in the same tissues.
Conclusions/Significance: These findings show that genetic heterogeneity is a peculiarity not only of cancer cells but also
of the normal tissue where a tumor arises.
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Introduction
There is ample evidence that tumours arise as a consequence of
genetic cell instability, which gives rise to an accumulation of
mutated genes. The tumour phenotype is expected to appear
when a critical number of transformation-related genes are
damaged [1,2,3,4]. Excluding tumours due to the effect of external
factors such as viruses [5], stem cells appear to be good candidates
for tumour origination because they are able to duplicate and have
not reached a final and stable genetic stage and because their
genomes must undergo reprogramming to express the proper
differentiated phenotype. In line with this hypothesis is the finding
that cultured tumour mouse erythroleukemia cells are particularly
sensitive to mutations in specific periods during erythroid
differentiation [6,7,8]. Random mutations are expected to occur
more frequently in nucleotide positions that are not relevant for
molecular functions and in genes not necessary to express a
differentiated phenotype. Consequently, it is likely that a stem cell
in which genetic instability arises does not lose the ability to
undergo clonal expansion and to differentiate participating in the
production of specific tissues. Under this assumption, genetic
instability that is originated in a particular stem cell may produce,
by clonal expansion, a number of cells in which further random
mutations are likely to occur. It is also possible that the genetically
unstable clones undergoing differentiation and final turnover may
disappear from the tissue. During the period in which the
genetically unstable stem cells are present and expand in the tissue,
the probability increases that mutations may damage the critical
transformation-related genes to produce a tumour phenotype. If
this mechanism is operative in the case of spontaneous tumours,
genes bearing mutations are likely to be observed not only in the
tumours but also in nearby cells showing a histologically and
functionally normal phenotype. Additionally, their genetic hetero-
geneity may be even higher than in tumour tissues. Data
concerning mutations in HPRT and G6PD genes, analyzed here
in two different colon tumours and nearby normal intestinal tissues
of two male patients, lend support to this hypothesis.
Materials and Methods
Ethics Statement
All samples were collected with appropriate ethics approval:
written informed consent for surgery to remove tumours and
verbal consent to analyze them were provided by both patients
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Surgery and Advanced Technology, School of Medicine, Univer-
sity of Naples Federico II. Reference blood samples were kindly
provided by two male individuals of the Department of Biological
Sciences, University of Naples Federico II, where this work was
carried out.
Patient Tissue Samples
Tumour tissues from two male Italian patients, a relapse of a
colorectum carcinoma (patient A, born in 1937) and a primary
colon sigma carcinoma (patient B, born in 1935), with corre-
sponding samples of nearby intestinal tissues assessed to be
histologically normal, were generously provided by the Depart-
ment of General Geriatric Oncological Surgery and Advanced
Technology, School of Medicine of the University of Naples
Federico II. Different tissue fragments were removed from each
sample to perform parallel independent analyses.
Reference Control Samples for Genetic Heterogeneity
Blood samples of two ostensibly healthy male individuals, one
22 years old (C1) and a second 76 years old (C2), were used as
reference controls of transcript heterogeneity to take into
consideration possible differences due to age.
Control Samples of Used Procedures
Two types of negative controls were used to check heterogeneity
arising from experimental procedures: 1 - Bacterial clones
containing a previously sequenced fragment of HPRT and
G6PD cDNA that were amplified, cloned and sequenced; 2-
HPRT and G6PD cDNA obtained from a human male CaCO-2
cell culture that were amplified, cloned and sequenced.
Preparation of Clones of Gene Transcripts
Total RNAs from tumour and healthy tissues of two patients
and from the blood of two reference individuals were prepared
using an SV Total RNA isolation kit (Promega, USA). cDNA
preparations were obtained using Superscript III and random
primers (Invitrogen, California). Both procedures were carried out
according to the respective manufacturers’ protocols. RT-PCR
amplifications of individual cDNAs were performed using
specific oligonucleotides for HPRT (NM_000194) and G6PD
(NM_000402.3). Also, TP53 (NM_000546) cDNA was amplified
to monitor genetic heterogeneity in a gene known to be involved in
tumours. Specifically, HPRT cDNA was amplified from nucleo-
tide position 16 to 526 using oligonucleotides forward CCT-
GGCGTCGTGATTAG and reverse GCTTATATCCAACA-
CTTCGTGG; G6PD cDNA was amplified from nucleotide
position 159 to 561 using oligonucleotides forward CGATG-
CCTTCCATCAGTCG and reverse GGACTCGTGAATGT-
TCTTGG; TP53 cDNA was amplified from nucleotide position
427 to 942 using oligonucleotides forward GTGCAGCTG-
TGGGTTGATTCC and reverse GGAGCTGGTGTTGTTG-
GGCAG. Numerations start from nucleotide A of ATG initial
triplets. PCR cycle conditions were initially 5 min at 94uC,
followed by cycles of 1 min at 94uC, 50 sec at 55uC, 50 sec at
72uC, and was repeated 35 times followed by 10 min at 72uC. The
annealing temperature was 58uC for HPRT amplifications. Clones
were amplified in 3 different PCR experiments from 3 different
cDNA preparations from each sample of tumour and healthy
tissues of patients and from reference and control samples using
Taq DNA polymerase (SIGMA, USA) or Expand High Fidelity
(Roche, USA), with similar results. Amplified cDNA fragments
were isolated by agarose gel electrophoresis, purified by NucleoS-
pin Extract II (Macherey-Nagel, Germany) and cloned using a
PCR cloning Kit (Qiagen, Germany). Individual clones were
randomly chosen and sequenced (MWG, Germany). The DNA
sequences of most clones showing mutations were confirmed by a
different sequencing unit (Zoological Station of Naples, Italy).
Nucleotide sequences were analyzed using Blast and ClustalW
algorithms.
Preparation of Clones of Genomic Regions
Genomic DNA was isolated with the Trizol reagent (Invitrogen,
California) from tumour tissues of patient A, which were also used
for RNA extraction. Exons 3, 4 and most of exon 5 (204/218 bp)
of the G6PD gene (ENST00000291567) were amplified by PCR as
a single amplicon of 1124 bp (total length of exons, 351 bp) by
designing the forward oligonucleotide in intron 1 (CAAGACA-
GACATGCTTGTGG) and the reverse oligonucleotide in exon 5
(GGACTCGTGAATGTTCTTGG). Exons 2, 3, 4 and 6 of the
HPRT gene (ENST00000298556) were amplified separately by
designing each oligonucleotide in the respective flanking intron
regions, taking care to produce segments of similar lengths. HPRT
exon amplifications were performed using the following pairs of
oligonucleotides, forward and reverse, respectively: CGAAC-
TCCTGAGCTCAGGCAG and GTTCTGGTCCCTACAGA-
GTCC for exon 2 (amplicon length 573 bp, exon length 107 bp);
TGTATTGCCCAGGTTGGTG and CAAGTCCCAACAG-
CAATTCC for exon 3 (amplicon length 540 bp, exon length
184 bp); CAGTAATGGCCGATTAGGAC and ACCTA-
GACTGCTTCCAAGGG for exon 4 (amplicon length 457 bp,
exon length 66 bp); GCTGTCATTGATCCTGCACC and
CTCTGCCATGCTATTCAGGAC for exon 6 (amplicon length
569 bp, exon length 83 bp).
PCR cycle conditions for HPRT exons 3, 4 and 6 were initially
5 min at 94uC, followed by 40 cycles of 50 sec at 94uC, 35 sec at
58uC, 45 sec at 72uC and finally 10 min at 72uC with the
following exceptions: the elongation time of G6PD was 70 sec at
72uC and the annealing temperature was 62uC for HPRT exon 2.
Amplified DNA fragments obtained from 3 different parallel PCR
experiments were pooled and purified by NucleoSpin Extract II
(Macherey-Nagel, Germany) and cloned using a PCR cloning Kit
(Qiagen, Germany). Individual clones were randomly chosen and
their insert DNAs were sequenced (MWG, Germany). Nucleotide
sequences were analyzed using Blast and ClustalW algorithms.
Statistical Analyses
Student t-distribution analyses were performed using an Excel
worksheet.
Frequency of Mutation
The frequency of mutations reported in this manuscript was
calculated for each sample with this formula: Total number of
detected mutations/(base pair length of the amplified fragments6
number of sequenced clones)61000, considering that all analyzed
samples were produced with the same number of PCR
amplification cycles.
Results
Transcript Analysis on Patient Tissue Samples
The single point mutations identified on the HPRT, G6PD and
TP53 transcripts are reported in Table 1, Table 2 and Table 3,
respectively. Analyses were performed by cloning and sequencing
the PCR-amplified segments of the cDNAs of the colon tumours
and nearby healthy tissues of patient A, bearing a tumour relapse,
and patient B, bearing a primary tumour. It should be noted that
Human Genetic Heterogeneity
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single X chromosome of human male cells and their nucleotide
sequence should be only one. In humans, G6PD is present only on
the X chromosome, while additional HPRT gene fragments are
present in several positions on other chromosomes, but none of
those fragments is expressed and, moreover, each would be easily
Table 1. Mutations in HPRT transcripts in tumour and nearby healthy tissues.
Patient and Tissue Type Mutations/clone Nucleotide position (mutation) Number of identical clones
A Healthy 1 66(TRC)u 1
A Healthy 1 150(TRC) 3
A Healthy 1 221(TRC) 1
A Healthy 1 386(ARG) 5
A Healthy 1 391(TRA)# 1
A Healthy 1 446(TRC) 1
A Healthy 1 447(GRT)u 1
A Healthy 1 490(CRT) 1
A Healthy 2 185(TRC) 274(TRC) 1
A Healthy 3 87(TRC) 190(GRA) 386(ARG) 1
A Healthy 0 wt 24/40 total clones
A Tumour 1 36(TRC) 1
A Tumour 1 66(TRC)u 1
A Tumour 1 100(ARG)* 2
A Tumour 1 119(GRA) 1
A Tumour 1 146(TRC) 1
A Tumour 1 245(TRC) 1
A Tumour 1 363(TRC) 1
A Tumour 1 414(CRT) 1
A Tumour 1 447(GRT)u 1
A Tumour 1 473(TRC) 1
A Tumour 2 193(CRT) 485(GRA) 1
A Tumour 2 81(TRC) 427(ARG) 1
A Tumour 2 112(CRT) 343(ARG) 1
A Tumour 2 270(TRC) 330(ARG) 1
A Tumour 2 231(CRT) 299(TRC) 2
A Tumour 5 200(TRA) 223(TRC)# 278(TRC) 447(GRA) 486(CRT) 2
A Tumour 6 153(ARC) 198(TRC) 355(GRA) 419(GRA) 431(ARG) 496(ARG) 1
A Tumour 0 wt 16/36 total clones
B Healthy 1 33(TRC) 1
B Healthy 1 59(ARG) 1
B Healthy 1 331(ARG) 1
B Healthy 1 400(GRA) 1
B Healthy 2 124(ARG) 388(GRA) 1
B Healthy 2 223(TRC)# 227(CRT) 1
B Healthy 2 308(ARG) 323(ARG) 2
B Healthy 0 wt 14/22 total clones
B Tumour 1 206(ARG) 1
B Tumour 1 215(ARG) 3
B Tumour 1 391(TRA)# 1
B Tumour 2 120(ARG) 147(TRC) 1
B Tumour 4 57(TRC) 100(ARG)* 302(GRA) 315(TRA) 1
B Tumour 0 wt 16/23 total clones
Mutations present in multiple clones in the same tissues are reported in bold-type, those present in different tissues are underlined. u, mutation in healthy and tumour
tissues of the same patient; *, mutation in the tumour tissues of patients A and B; #, mutation in both the healthy tissues of patient A and the tumour tissues of patient
B. Numeration of nucleotide positions starts from A of the initial ATG triplet. wt: wild type sequence.
doi:10.1371/journal.pone.0009343.t001
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sequenced region [9].
HPRT transcripts, proposed as a probe of gene instability in
human cells [10,11,12], have shown the largest variety of
mutations also in the present work. A total of 121 HPRT clones
were sequenced and 51 of them showed mutations (Table 1). In
particular, the highest percent value of mutated HPRT clones
(55%) was found in the carcinoma relapse of patient A (20 mutated
in 36 sequenced clones). A similar genetic heterogeneity resulted
from the healthy tissues of patient A and from the healthy and
tumour tissues of patient B (40%, 36% and 30% mutated clones,
respectively). The high number of point mutations observed in
some HPRT clones, up to 6 (Table 1), is difficult to rationalize on
the basis of frequency of errors derived from cell division. As
already suggested [10], this high number might indicate the
activity of a mutator phenotype. Significantly, clones with identical
single point mutations were present in healthy and tumour tissues
of patients A and B.
Data concerning heterogeneity in G6PD transcripts showed
similar percent values of mutated clones in the cancer and healthy
tissues of both patients A and B, with about 34% average value
(Table 2). In the 107 sequenced clones, 35 showed mutations.
Single point mutations, as observed for HPRT gene transcripts,
were present in both tumour and healthy tissues. Furthermore
some clones were found bearing mutations at the same sequence
position, in some cases a transition and in others a transversion.
For example, 1 clone of the healthy tissue of patient A showed the
transition T.C at nucleotide 503, whereas 1 clone of the healthy
tissue of patient B shows the transversion T.A.
Data concerning TP53 transcripts, analyzed here as a gene
generally correlated to tumours, involved a lower number of
clones. In humans, transcripts of this gene present on chromosome
17 might show difference(s) due to heterozygosity, but all of the
analyzed clones of the healthy tissues of patient B showed the
identical normal sequence. The corresponding tumour tissues
showed a value of percent mutated clones (Table 3) that was too
low to be indicative of heterogeneity in the procedure used here,
particularly considering the results reported below on control
samples and the small number of analyzed clones. Interestingly, in
both healthy and tumour tissues of patient A, bearing a colorectum
carcinoma relapse, all observed single point transitions in TP53
transcripts, with the exception of mutations at position 628 (A.G)
and 789 (T.C), have been reported in a different tumour [IARC
TP53 mutation database, 13].
Reference and Control Samples
HPRT transcripts. Reference control analyses for
heterogeneity of HPRT transcripts were carried out with the
same experimental approach by sequencing 10 clones from each
blood sample of C1 and C2 ostensibly healthy individuals. The
results on C1, a 22 year old male, showed 1 clone with a single
point mutation and 2 clones with 2 point mutations, all different
from each other. Similar analyses on C2, a 76 year old male,
showed 3 clones with single point mutations, all different from
each other and from those observed in the tumour and nearby
healthy tissues of the two patients analyzed here. Errors due to the
analytical procedure were evaluated by sequencing 42 control
clones obtained from an already cloned and sequenced HPRT
segment. A 7% value of mutated clones resulted as error due to the
procedure (Fig. 1A and 2A).
G6PD transcripts. Reference control analyses for G6PD
transcript heterogeneity on healthy individuals, as for HPRT
analyses, were performed on 10 clones of both C1 and C2 blood
cDNA samples. 10 cDNA clones were also prepared from the
human colon carcinoma cell line CaCO-2 and analyzed as
controls. In both cases, 2 clones out of 10 showed mutations.
G6PD transcripts from CaCO-2 cells showed a clone with a single
point mutation and another with 2 point mutations. In total, 6
clones out of 30 were mutated, corresponding to a 20% value. The
analytical procedure, tested on 20 clones obtained from PCR
amplification and cloning of an already sequenced G6PD
Table 2. Mutations in G6PD transcripts in tumour and nearby
healthy tissues.
Patient and
Tissue Type
Mutations/
clone
Nucleotide position
(mutation)
Number of
identical clones
A Healthy 1 276 (CRT) 1
A Healthy 1 301 (GRA) 1
A Healthy 1 484 (TRC)u 1
A Healthy 1 494 (ARG) 1
A Healthy 1 503 (TRC)+ 1
A Healthy 1 510 (GRA) 1
A Healthy 1 526 (GRA) 1
A Healthy 2 199 (ARG) 468 (TRC) 1
A Healthy 2 261 (GRA) 300 (TRC) 2
A Healthy 0 wt 17/27 total clones
A Tumour 1 182 (CRT) 1
A Tumour 1 188 (TRC) 1
A Tumour 1 218 (TRC) 1
A Tumour 1 289 (ARC) 1
A Tumour 1 361 (ARG) 1
A Tumour 1 392 (TRC) 1
A Tumour 1 413 (TRC) 1
A Tumour 1 484 (TRC)u 1
A Tumour 0 wt 17/25 total clones
B Healthy 1 185 (ARC) 1
B Healthy 1 333 (CRT) 1
B Healthy 1 401 (GRA) 1
B Healthy 1 425 (ARG) 1
B Healthy 1 459 (CRT) 1
B Healthy 1 503 (TRA)+ 1
B Healthy 1 541 (ART)u 1
B Healthy 2 229 (ART) 370 (GRA) 1
B Healthy 2 259 (CRG) 487 (CRT) 1
B Healthy 2 278 (ARG) 522 (GRA) 1
B Healthy 0 wt 21/31 total clones
B Tumour 1 251 (GRA) 1
B Tumour 1 310(CRT) 1
B Tumour 1 430 (GRA) 1
B Tumour 1 465 (GRA) 1
B Tumour 1 467 (ARG) 1
B Tumour 1 541 (ARG)u 2
B Tumour 0 wt 17/24 total clones
Mutations present in multiple clones in the same tissues are reported in bold-
type, those present in different tissues are also underlined. u, mutation in
healthy and tumour tissues of the same patient, +, mutation in the healthy
tissues of both patients A and B. Numeration of nucleotide positions starts from
A of the initial ATG triplet. wt: wild type sequence.
doi:10.1371/journal.pone.0009343.t002
Human Genetic Heterogeneity
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corresponding to 20% mutated clones (Fig. 1B and 2B).
Statistical Analysis on Transcript Samples
Percent mutated clones relative to the 3 series of independent
experiments performed for HPRT (Panel A) and G6PD (Panel B)
with respective standard deviations are reported in Figure 1. It is
apparent from the comparison between the standard deviation
values that the cancer and nearby healthy tissues were heteroge-
neous materials, while the reference samples and control clones
were homogeneous. Statistical analyses with the student’s t-test
were performed comparing, for each gene, percent values of total
mutated clones from tumour and healthy tissues of patient A and B
samples versus percent of total mutated control clones (Fig. 2). The
results show that the values of genetic heterogeneity found in
cancer and histologically healthy tissues of the two patients for
both HPRT (Fig. 2A) and G6PD (Fig. 2B) transcripts are
statistically similar to each other and different from the controls.
Specifically, for HPRT transcripts, the percent mutated clones in
the 121 sequenced for patient A and B healthy and cancer tissues,
analyzed versus percent values of 62 control clones, resulted in
p=0,0066, while the student’s t-test on patient A versus patient B
resulted in p=0,2. Similar analyses for 107 total G6PD clones
versus 50 control samples resulted in p=0,0021. No statistical
difference resulted comparing patient A and patient B values
(p=0,25).
Genomic Analysis on Patient Tissue Samples
To get some insights into the mechanism(s) underlying the
genetic heterogeneity found in HPRT and G6PD mRNA
sequences, we analyzed the genomic DNA fragments correspond-
ing to the transcript regions under investigation with the same
experimental approach. We performed these analyses on genomic
DNA from the tumour tissues of patient A that showed the highest
percent of mutated clones. The single point mutations identified
on the HPRT and G6PD genomic regions are reported in Table 4
and Table 5, respectively. HPRT exons 2, 3, 4 and 6 were
amplified in 4 different genomic segments due to the lengths of the
introns, while G6PD exons 3, 4 and 5 were amplified in a single
genomic fragment. In particular, for HPRT sequence analyses
(Table 4), 25 clones out of 60 showed mutations occurring in exon
and intron regions. In detail, 6 clones showed single point
mutations in exons 3 and 4, and four of these clones had the same
A.G transition at nucleotide 239; one clone showed 2 point
mutations in exon 2, and 1 of these, at nucleotide 57, was already
identified in HPRT transcript analysis on tumour tissues of patient
B. No clone showed mutations in exon 6. Other mutations were in
intron regions.
Data concerning G6PD genomic regions (Table 5) showed that
11 clones out of the 20 sequenced displayed mutations; 5 clones
showed single point mutations in exons 4 and 5, and two of these
clones had an identical T.C transition at nucleotide 329; one
clone showed 2 point mutations in exon 4. No clone showed
mutations in exon 3. Other mutations were in intron regions.
The percent values of mutated clones of HPRT (Fig. 2C) and
G6PD (Fig. 2D) genomic regions are reported in Figure 2. These
two genes show similar genetic heterogeneity because, in both
cases, 50% mutated clones were observed. The average value of
percent mutated clones of each analyzed HPRT genomic
fragment is reported with the standard deviation (Fig. 2C).
To compare the results on G6PD and HPRT genes to their
transcripts in all of the analyzed samples, the frequencies of
mutation were calculated considering the number of sequenced
clones and the lengths of each amplified fragment (Fig. 3). The
genomic mutation frequencies are reported both for exons and for
the entire sequenced DNA regions, including introns. The results
on the HPRT gene (Fig. 3A) show that the values of mutation
frequency of reference C1 and C2 transcripts are statistically
different from the control samples (p=0.006). No significant
difference was observed when comparing the cDNA mutation
frequencies of C1 and C2 reference controls, patient A healthy
tissues and patient B tumour and nearby healthy tissues with
mutation frequencies of the respective genomic sequences
(p.0.05). Overall, these data indicate that heterogeneity found
in HPRT cDNA clones has a somatic origin. HPRT heterogeneity
appears to be independent of age (22 and 76 years), health, cancer
Table 3. Mutations in TP53 transcripts in tumour and nearby healthy tissues.
Patient and Tissue Type Mutations/clone Nucleotide position (mutation) Number of identical clones
A Healthy 1 536 (ART) 1
A Healthy 1 628 (ARG) 1
A Healthy 2 535 (CRT) 874 (ARG) 1
A Healthy 2 647 (TRC) 681 (TRC) 1
A Healthy 2 655 (CRT) 915 (GRA) 1
A Healthy 0 wt 10/15 total clones
A Tumour 1 461 (GRA) 1
A Tumour 1 545 (GRA) 1
A Tumour 2 574 (CRT) 789 (TRC) 1
A Tumour 2 543 (CRT) 635 (TRC) 1
A Tumour 0 wt 7/12 total clones
B Healthy 0 wt 12/12 total clones
B Tumour 1 631 (ARG) 1
B Tumour 1 831 (TRC) 1
B Tumour 0 wt 8/10 total clones
Numeration of nucleotide positions starts from A of the initial ATG triplet. wt: wild type sequence.
doi:10.1371/journal.pone.0009343.t003
Human Genetic Heterogeneity
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mutation frequency of transcripts in the tumour tissues of patient
A differed from the others and, in particular, from the mutation
frequencies of its corresponding genomic regions. This suggests
that, in this case, mutations are introduced during processes
leading to mRNAs.
The results on the G6PD gene (Fig. 3B) show that the mutation
frequency values of the C1 and C2 reference samples were not
different from controls (p.0.05), indicating that healthy people,
regardless of age, show no significant genetic heterogeneity in this
gene. However, the values of the G6PD mutation frequency of
reference healthy individuals were statistically different from those
of the transcripts and of the corresponding genomic regions of
both patients (p=0.009), indicating that G6PD genetic heteroge-
neity is specific of cancer and nearby healthy tissues in the two
studied colon tumours.
Discussion
The results presented here provide evidence of a similar value of
genetic heterogeneity in HPRT and G6PD transcripts in cells of
colon carcinoma and nearby healthy tissues in the two studied
patients. The mutation frequencies of the HPRT and G6PD gene
sequences of patient A were found to be not statistically different
from the corresponding values of the cDNAs. This indicates that
the mutations are present in genes and not introduced in the steps
that produce mRNAs. Only mutation frequencies of cDNA of the
colorectum carcinoma relapse were higher than the corresponding
Figure 2. Percent mutated clones of HPRT and G6PD cDNA and
genomic regions. Panel A, values of HPRT transcripts; Panel B, values
of G6PD transcripts. Panel C, values of HPRT genomic regions; Panel D,
values of G6PD genomic regions. Percent values have been calculated
on pooled data from each independent analysis. AT and BT, values of
clones of Tumour tissues of patients A and B, respectively; AH and BH,
values of clones of Healthy tissues near tumours. C1 and C2, values of
reference samples. Clones, values of control samples.
doi:10.1371/journal.pone.0009343.g002
Figure 1. Standard deviations of percent mutated clones of
HPRT and G6PD cDNAs. Analyses of 3 independent experiments for
each gene on tumour and healthy tissues of patients A and B, on
reference samples C1 and C2, and on control clones. Panel A, values of
HPRT transcripts; Panel B, values of G6PD transcripts. AT and BT, values
of clones of Tumour tissues; AH and BH, values of clones of Healthy
tissues nearby tumours. Clones, values of control clones.
doi:10.1371/journal.pone.0009343.g001
Human Genetic Heterogeneity
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additional mechanism(s) that produce mutations in the processes
leading to mRNAs.
It is interesting to note that the standard deviation values of
percent mutated clones of patient tissues were dramatically
different from the corresponding values of the two reference
blood samples of healthy individuals and from the control clones
(Fig. 1). This suggests that patient tissues are heterogeneous
materials, in line with the hypothesis of cellular genetic
heterogeneity in tumours [14], while healthy reference samples
and controls appeared to be homogeneous, as expected.
In agreement with previous data on the DNA of circulating T-
lymphocytes [10,11,15,16], our data clearly show genetic
heterogeneity for HPRT in healthy individuals (Fig. 3A). The
present work, however, provides evidence that HPRT heteroge-
neity is present not only in blood samples but also in intestinal
colon tissues with similar values, indicating that this genetic
heterogeneity is a characteristic of the gene and is not a
consequence of genomic rearrangements occurring in a particular
tissue. Conversely, the heterogeneity found for the G6PD gene
and transcripts in reference healthy individuals had values
significantly lower than those of patient tissues and similar to
those of control clones (Fig. 3B), showing that heterogeneity in this
gene is a peculiarity of the tumour and the nearby healthy tissues.
The observed high percent of mutated cDNA clones (Fig. 2A
and B) should occur during the life span of the cell because only
about 1610
28 base pairs are incorporated as erroneous nucleo-
tides per cell division [17]. DNA mutations are reported to be
produced in other functional steps, such as the transcription-
coupled repair process [18] that has been proposed to be
responsible for SNP in human genes [19]. The different
frequencies of gene mutations observed here could depend on
different gene expression levels and/or on local chromatin
organization [20,21,22,23]. However, other mechanisms have
been proposed through which epigenetic factors might give rise to
localized nucleotide changes in DNA composition. Environmen-
Table 4. Mutations in HPRT gene regions in tumour tissues of patient A, colorectum carcinoma relapse.
Number of clones Exon 2 (107 bp) Exon 3 (184 bp) Exon 4 (66 bp) Exon 6 (83 bp)
Number of Mutations
in Introns
14 5 ( A RG) 57 (TRC)* 4
1 3
1 2
3 1
9/15 total clones wt wt
4 239 (ARG)
2 2
2 1
7/15 total clones wt wt
1 374 (TRC) 1
1 320 (ARG)
3 1
10/15 total clones wt wt
6 1
9/15 total clones wt wt
Numeration of nucleotide positions of exons starts from A of the initial ATG triplet of the coding sequence. *, mutation already identified in cDNA samples from tumour
tissues of patient B. wt: wild type sequence.
doi:10.1371/journal.pone.0009343.t004
Table 5. Mutations in the G6PD gene region in tumour tissues of patient A, colorectum carcinoma relapse.
Number of clones Exon 3 (38 bp) Exon 4 (109 bp) Exon 5 (204 bp) Number of Mutations in Introns
12 5 4 ( T RC) 335 (ARG)
23 2 9 ( T RC) 2
1 418 (GRA)
1 464 (TRC)
1 531 (CRT)
4 1
1 2
9/20 total clones wt wt wt wt
Each clone was sequenced on both filaments. Numeration of nucleotide positions of exons starts from A of the initial ATG triplet of the coding sequence. wt: wild type
sequence.
doi:10.1371/journal.pone.0009343.t005
Human Genetic Heterogeneity
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enzymes can lead to changes in DNA sequences. If these changes
occur in somatic cells, the resulting mutations might be important
in triggering disease states [reviewed in 24].
Recently, it has been documented that a tumour may derive
from one single genetically unstable cell [25]. Our data show that
several unstable cells seem to be present in normal tissues where a
tumour arises. It should be noted that the genetic heterogeneity
here found might not be revealed if sequence analyses are carried
out directly on the products of PCR amplification. This is
apparent considering that in the experiments presented here, a
minimum of 45% of clones were found with the same wild type
sequence, while a maximum of 5 clones out of 40 were found with
an identical mutated position (HPRT transcripts showing (A.G)
at nucleotide position 386 in tumour tissue of patient A),
corresponding to 15% relative abundance (Table 1). This percent
value has no appreciable effect on the amplitudes of the sequential
pattern of bands produced by the analyzing platforms that detect
the more abundant nucleotides.
It is known [26], and we found here, that the procedure based on
sequencing several individual clones is affected by possible errors
due to the amplification step by Taq DNA polymerase. This
enzyme introduces erroneous bases with a statistical frequency of
about1every5000polymerizednucleotides.Tocompensateforthis
error, we performed all PCR amplification reactions rigorously
under the same experimental conditions using an identical number
of cycles. In this way, the frequency of mutation of samples and
controls can be directly compared to evaluate background error
contribution. The results reported here on control samples show a
frequency of error spanning from 1/2000 (G6PD control clones) to
1/5000 (HPRT control clones), depending on the sequence
composition, possibly because of the known nearest neighbour
nucleotide effect on the accuracy of replication [27,28]. Results on
the isolation of mutated clones by amplification of the particular
variants directly on the cDNA samples using modified oligonucle-
otides [29, and references therein] are not presented here because
low levels of false positives were generated. For this reason, we
decided to avoid any screening criterion of the data and analyze
them comparing the frequency of erroneous inserted nucleotides as
determined on the basis of the number and lengths of the sequenced
clones. This analytical approach revealed values of TP53 mutation
frequency, evaluated on the 49 analyzed clones, that were slightly
above the largest error value determined in control experiments.
This indicates that the single nucleotide mutations, observed here
and reported in the TP53 mutation database [13], might really
correspond to the background genetic noise, and not be specifically
correlated to tumour formation. The low mutation frequency
observed for TP53 on sample tissues where other genes show higher
values confirms that genes may be differently affected by
background genetic noise. The possibility that the source of most
of the mutations presented here might depend on the reverse
transcriptase infidelity is not apparent in our results. Indeed, G6PD
heterogeneity was similar for C1 and C2 reference samples and for
control clones (Fig. 2B and 3B). However, C1 and C2 RNA samples
were reverse-transcribed and then amplified by PCR, while control
clone DNA samples were only PCR-amplified. The reverse-
transcription step did not add any appreciable increase in either
percent mutated clones (Fig. 2B) or frequency of mutation values
(Fig. 3B).
Overall, the results reported here appear relevant to a
mechanism of spontaneous tumour formation by providing
information on the variety of mutations occurring in a gene, and
by complementing the results of massive global genomic analyses
performed on tumour tissues [30,31]. Our finding of a similar
genetic heterogeneity in colon cancer tissues, nearby healthy
tissues and in reference healthy samples for the HPRT gene is also
an indication that some genes have physiologically low levels of
mutations. Normally, this heterogeneity may have no functional
effects and escape detection with commonly used analytical
procedures. It was revealed here because the cumulative
abundance of each single nucleotide substitutions results in a
number of mutated clones, each randomly representing the variety
of mutations occurring in the analyzed tissues, which can be
detected by the cloning procedures. When the spontaneous low
background genetic heterogeneity increases and hits relevant
genes, spontaneous tumours may arise. This implies that no
general patterns of gene mutation and no sequential set of gene
modifications are expected, although each tumour, depending on
its type and tissue of origin, may present more frequent mutations
in the particular genes that are active in the particular
differentiated tissue.
Our approach, based on comparing genetic heterogeneity in
tumour and nearby healthy tissues, if confirmed by further
analyses on other genes, may help to distinguish spontaneous and
induced tumours and may be useful for tumour follow-up.
Figure 3. Mutation frequency values of all analyzed sequences
of HPRT and G6PD cDNA and genes. Panel A, values of HPRT
sequences; Panel B values of G6PD sequences. AH, AT, BH, BT: values
calculated for cDNA clones of Tumour and nearby Healthy tissues of
patients A and B. C1 and C2: values for cDNA clones from blood tissues
of 2 healthy reference individuals. AT gene: values for clones of global
genomic regions of DNA from tumour tissues of patient A. AT exons:
values for the exon regions of the sequenced genomic regions.
Controls: values for clone samples.
doi:10.1371/journal.pone.0009343.g003
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